Phase 2 Clinical Trial Approved

The Israeli Ministry of Health has approved our groundbreaking study, which will test the safety and efficacy of our neuroprotective cannabinoid therapeutic to treat autism related spectrum disorders (ASD) and other neuropsychiatric illnesses.

A Growing Need

ASD affects more than 5 million children today in the US, costing more than $115 Billion per year.

Yet, existing pharmaceutical treatments are only marginally effective and can cause significant side effects.

Meeting the Challenge to Treat the Core Symptoms of ASD With a More Effective Therapeutic

GCANRx is focused on the development and commercialization of an innovative pharma-grade therapeutic that reduces the disruptive symptoms in patients suffering from neuropsychiatric disorders without the side effects of existing medications.